An interventional study of Physical activity in Sarcopenia and Frailty, sponsored by Ministry of Health, Thailand. Completed at 1 site in Thailand. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by Ministry of Health, Thailand · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Sarcopenia with a site in Thailand — 6 open to participants now, 6 under way, 1 of them phase 3. Sarcopenia · Thailand.
Among the 12 studies in Sarcopenia with a site in Thailand, this one is one of 2 that started in 2021, is one of 6 with no phase, and was the 4th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →6 of the 12 studies in Sarcopenia with a site in Thailand are open now. Recruiting first, the newest first:
Prince of Songkla University · Sites in Thailand
Ages 18+ · Healthy volunteers
Chulalongkorn University · Sites in Thailand
Ages 65+
Mahidol University · Sites in Thailand
Ages 18–75
Mahidol University · Sites in Thailand
Ages 18–85
Abbott Nutrition · Sites in Thailand
Ages 55–99
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 60 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 360 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 65 across the 8 interventional studies, 202 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 7 most frequent:
Ministry of Health, Thailand is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Ministry of Health, Thailand has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Sarcopenia with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sarcopenia and frailty could be prevented and rehabilitated through individual physical activities in the form of combined exercise that could be practiced at home in daily life.
The volunteers were randomly assigned to either the intervention or control group using sealed envelopes containing documents marked with either IG (intervention group) or CG (control group). The intervention group received training, after which they demonstrated and practiced the physical activities. They were provided with an exercise leaflet for self-practice at home and were followed up by phone, LINE application, and leaders of social club for older adults at least once a week to ensure regular practice. The older adults' relatives and caregivers were also trained and encouraged to practice with them in a 1:1 match. Support techniques and warning signs for stopping or taking a break during exercise were added to each posture, along with suggestions for suitable environmental management, such as flat plains, sufficient light, and no barriers within 2 meters, to reduce the risks of accidents. However, the control group did not receive any intervention apart from general suggestions and continued with their usual daily activities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Experimental groups or physical activity groups were assigned to three groups based on their muscle mass: normal, probable sarcopenia, and sarcopenia groups. The volunteers were provided with instructions on individual physical activities to be practiced at home for 30 weeks, 2-5 days per week and 50 minutes per session. These physical activities consisted of flexibility exercise for 10 minutes, aerobic exercise for 20 minutes, and resistance exercise for 20 minutes, as outlined in supplement 1. The volunteers were instructed on exercise techniques and physical activities by either sports scientists or registered nurses, and caregivers such as relatives or staff from the social club for older adults were allowed to be present during practice.
Behavioral: Physical activity
The control group did not receive any intervention apart from general suggestions and continued with their usual daily activities.
resistance, aerobic, and flexibility exercises
The status of sarcopenia aligns with the criteria set by the Asian Working Group for Sarcopenia (AWGS).
Sarcopenia status was assessed through three aspects, including a muscle strength test using handgrip strength measured with a dynamometer, a physical performance test using the Short Physical Performance Battery (SPPB), and an appendicular skeletal muscle mass (ASM) test measured with the ACCUNIQ BC 380 tool based on bioelectrical impedance analysis (BIA). The results were aligned with the standards set by the Asian Working Group for Sarcopenia (AWGS). Sarcopenia was diagnosed by low ASM with low muscle strength or low physical performance, dynapenia was diagnosed by low muscle strength only, and pre-sarcopenia was diagnosed by low ASM or low physical performance. Participants underwent assessments both at the beginning and at the 30-week endpoint.
Time frame: 30 weeks
Muscle strength
Muscle strength, specifically handgrip strength, was measured using a hand-held dynamometer. Participants gripped the dynamometer with their dominant hand while standing, maintaining their upper arm close to the body and their elbow bent to 90 degrees, exerting maximum force. This test was conducted twice, and the superior result was recorded. Low muscle strength was diagnosed if the handgrip strength was \< 26 kilograms in males and \< 18 kilograms in females. Participants underwent assessments at both the beginning and the 30-week endpoint.
Time frame: 30 weeks
Physical performance
The physical performance test utilized the Short Physical Performance Battery (SPPB) to evaluate physical function, with a maximum score of 12 points. Low physical performance was diagnosed if the SPPB score was ≤ 9. Participants underwent assessments at both the beginning and the 30-week endpoint.
Time frame: 30 weeks
Muscle mass
Appendicular skeletal muscle mass (ASM) was measured using the ACCUNIQ BC 380 tool based on bioelectrical impedance analysis (BIA), and the Skeletal Muscle Mass Index (SMI) was calculated by dividing ASM in kilograms by the height in meters squared. Low muscle mass is diagnosed if SMI is \< 7.0 kilograms/meter\^2 in men and \< 5.47 kg/m\^2 in women. Participants underwent assessments at both the beginning and the 30-week endpoint.
Time frame: 30 weeks
Physical frailty status based on the 5 criteria of frailty phenotype, as defined by Fried et al. 2001.
Frailty phenotype assessment followed Fried et al.'s (2001) criteria, including weakness, slowness, unintentional weight loss, exhaustion, and low physical activity. Participants were categorized as "frail" if they met three or more criteria, "pre-frail" with one or two, and "robust" if none were fulfilled. (i) Weakness: Handgrip strength measured with a dynamometer. (ii) Slowness: Assessed by the time taken in a 15-feet walk test. (iii) Unintentional Weight Loss: Evaluated by recording weight loss exceeding 10 pounds or 5% in the last 3 months. (iv) Exhaustion: Assessed with two questions from the CES-D depression scale. (v) Low Physical Activity: Determined by asking about the frequency of moderate physical activities in the past week. Participants underwent assessments at both the beginning and the 30-week endpoint.
Time frame: 30 weeks
Plan to share: Yes — Yes: There is a plan to make IPD and related data dictionaries available : all IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Starting 6 months after publication
Access criteria: Access Criteria: Ethical Approval: Requestors must provide evidence of ethical approval from their respective institutions or review boards for the proposed analyses. Data Security Measures: Researchers must demonstrate the implementation of robust data security measures to protect the confidentiality and integrity of the shared data. Additional Supporting Information: Study Protocol: A detailed study protocol outlining the objectives, methodologies, and analysis plan must be submitted along with the request for IPD access. Data Dictionary: A comprehensive data dictionary defining variables, codes, and any transformations applied to the data should accompany the request.
Data sharing details ↗ · nutrition2.anamai.moph.go.th
Ran from Mar 2021 to primary completion in Feb 2022, 11 months.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 11 months is below that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ministry of Health, Thailand